# data[].attributes.body
Parents

1. We are writing to our parents and it is more casual, probably over text message.

2.  The relationship between our parents is very close, so we would use comfortable language while also staying respectful.

3. I want my parents to approve of what I say, while also trusting me to make my own decisions.

4. We would write a long paragraph explaining how we met, who he is, and why they should approve. This way they will be more open to approving them.

5. We are writing this to gain our parents support and approval for our new relationship.

Friends

1. We are writing to our friends. It's more of a simple conversation, less of looking for approval and more honest and exciting conversation, not serious. Probably done over text.

2. We are very close and more personal. Being less formal in message and using more “slang” language.

3. I just want support from my friends, being excited and accepting the actions that I a, taking.

4. My writing format towards my friend would be less formal and more personal, it would most likely be very detailed and full of slang words.

Instructor

1. We are writing to tell our instructor that we are in a relationship, probably in an email. The reason would most likely be because we forgot to do an assignment due to our relationship or just simply trying to share more with our professor.

2. The relationship is professional and more formal language would need to be used. Minimal slang words and just the facts on a very surface level because we are not that close to our professor

3. Want the professor to understand that your personal life got in the way of your educational life.

4. The writing format towards our professor would be very professional, so it would not include all the details and stay very brief to be respectful.

5. I would write it to allow my professor to get to know me better as a student and increase his understanding that I have a life outside of his class.

# data[].attributes.body
I worked for a cheer brand as a cheer instructor teaching high school students material and how to stunt/cheer safely while also doing harder skills. So when I am talking with my co-workers it's less formal and more fun, you can use whatever language you want. But when communicating with my boss it is usually over email but in my email I am definitely more formal with my language. And when I am communicating with HS coaches I am professional and formal but when communicating with the kids it's more fun but still professional.

# data[].attributes.attachment_link.readable_text
Nature Medicine explores the latest translational and clinical research news, with a newly approved JAK and TEC inhibitor for the autoimmune disease alopecia areata.

The US Food and Drug Administration (FDA) has approved ritlecitinib, an inhibitor of JAK3 and the TEC family, from Pfizer, for adults and children 12 years of age and older who suffer from severe alopecia areata. The positive decision is based on the results of the ALLEGRO phase 2b/3 trial, which enrolled 718 adolescents and adults who had scalp hair loss of 50% or more. The trial's primary endpoint was achievement, at week 24, of a score of 20 or less on the absolute severity of alopecia tool (SALT), which runs from 0 to 100. ALLEGRO included four different dosing regimens, all of which met the primary endpoint (a fifth group that received a low dose of 10 mg was analyzed only for pharmacokinetics and safety and was not included in the comparison with placebo). In the highest-dose arm of the trial, 31% of patients had a SALT score of 20 or less, versus 2% in the placebo arm.

Access options

Additional access options:

Nature Medicine 29, 2144-2145 (2023)
doi: https://doi.org/10.1038/d41591-023-00065-z
The Clinical Pipeline is a column on translational and clinical research, from bench to bedside

# data[].attributes.attachment_link.title
FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss

# data[].attributes.attachment_link.description
Nature Medicine explores the latest translational and clinical research news, with a newly approved JAK and TEC inhibitor for the autoimmune disease alopecia areata. Nature Medicine explores the latest translational and clinical research news, with a newly approved JAK and TEC inhibitor for the autoimmune disease alopecia areata.